Candel Therapeutics Inc (CADL) Stock Price, Quote & News

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 916 5445

Website: www.candeltx.com

Address:

117 Kendrick Street, Suite 450, Needham, United States

__AvengerTrader Dec. 4 at 11:37 PM

What is happening to ticker SNSE now?! Looks like they are going to SQUEEZE ticker SNSE up next .. SNSE is breaking out like crazy.. Its insane what's going on in this market.. Looks like all eyes are going to SNSE now.. $CADL $COEP $BETR $CJET **

0 · Reply

CO145 Dec. 4 at 11:23 PM

$CADL @GordonGecko_was_THE_MAN Sounds like FDA considering making one P3 standard vs the current norm of two P3 trials. This should ease your mind regarding the singular Cadl prostate P3.

1 · Reply

Groov Dec. 4 at 11:14 PM

$CADL $18 per Billion.

0 · Reply

Floyd_Dalton Dec. 4 at 11:07 PM

$CADL 10 Billion is well over $100 sp

0 · Reply

svertical1 Dec. 4 at 10:54 PM

$IBRX $CADL $NTLA $CRSP should have doubled today, if not more!

1 · Reply

deporte1800 Dec. 4 at 9:39 PM

$CADL very interesting https://www.statnews.com/pharmalot/2025/12/04/fda-vaccines-pazdur-makary-kennedy-cassidy-vaccines-novo-alzheimers/

0 · Reply

deporte1800 Dec. 4 at 9:37 PM

$CADL Major announcement today: FDA head Makary told STAT news that he is proposing that all all medical products should only need 1 pivotal trial for approval. Which means instead of a Ph2 and Ph3 it would only need one of them. Typically Ph2 has less participants so it&#39;s expected that those numbers will increase if Ph3 is skipped. Right now due to fast track designations about 66% of drugs are approved after a Ph2 anyway. TIMING: Policy people are expecting a lot of pushback here so it&#39;s not a sure thing - From STAT: The agency will publish a press release soon, a spokesperson later told us. Makary said the agency will also start updating policies to reflect the change, which could take three to six months. The change will take effect once the guidance is updated.

1 · Reply

Drcando Dec. 4 at 9:04 PM

$CADL Strong Volume today

0 · Reply

ShadowBull3745 Dec. 4 at 9:04 PM

$CADL

0 · Reply

minnesotafarmcountry Dec. 4 at 8:44 PM

$CADL MMs have been collecting shares all day … who sells into a change in sentiment/direction?

1 · Reply

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 13, 2025, 8:25 AM EST - 21 days ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

Nov 4, 2025, 9:00 AM EST - 4 weeks ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 3, 2025, 8:05 AM EST - 4 weeks ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Oct 16, 2025, 8:05 AM EDT - 7 weeks ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Oct 14, 2025, 8:10 AM EDT - 7 weeks ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 7 weeks ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Oct 14, 2025, 8:05 AM EDT - 7 weeks ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 13, 2025, 10:22 AM EDT - 7 weeks ago

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now

Oct 3, 2025, 9:05 AM EDT - 2 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Sep 29, 2025, 8:05 AM EDT - 2 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 2 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 7, 2025, 10:53 AM EDT - 3 months ago

Candel Therapeutics: Potentially The Next Exciting Oncology Story

Sep 5, 2025, 12:47 PM EDT - 3 months ago

Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors

Sep 2, 2025, 8:05 AM EDT - 3 months ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Aug 28, 2025, 8:05 AM EDT - 3 months ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 14, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jul 30, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 9, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jun 24, 2025, 9:05 AM EDT - 5 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 23, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 6, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

May 28, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 27, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 22, 2025, 5:05 PM EDT - 7 months ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 13, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 6, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Apr 23, 2025, 4:05 PM EDT - 8 months ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 1, 2025, 8:01 AM EDT - 8 months ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Mar 26, 2025, 4:05 PM EDT - 9 months ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Mar 20, 2025, 8:00 AM EDT - 9 months ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 18, 2025, 8:00 AM EDT - 9 months ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Mar 13, 2025, 4:15 PM EDT - 9 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Feb 25, 2025, 4:52 PM EST - 10 months ago

Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data

Feb 25, 2025, 8:00 AM EST - 10 months ago

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Feb 20, 2025, 10:45 AM EST - 10 months ago

Candel Therapeutics: Entering Its Pivotal Year

Jan 13, 2025, 8:00 AM EST - 11 months ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Jan 2, 2025, 11:46 PM EST - 11 months ago

Best-Performing Stocks Of 2024

APP BYRN DAVE INOD JANX LUNR MSTR

Dec 16, 2024, 4:01 PM EST - 1 year ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 8:53 AM EST - 1 year ago

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

EGHT

Dec 12, 2024, 11:00 PM EST - 1 year ago

Candel Therapeutics Announces Pricing of Public Offering

Dec 12, 2024, 4:51 PM EST - 1 year ago

Candel Therapeutics Announces $80 Million Proposed Public Offering

Dec 11, 2024, 12:19 PM EST - 1 year ago

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Dec 11, 2024, 9:19 AM EST - 1 year ago

Candel Therapeutics Stock Surges Over 100% - Here's Why

Dec 11, 2024, 7:09 AM EST - 1 year ago

Candel Therapeutics' cancer drug meets late-stage trial goals

Dec 11, 2024, 7:00 AM EST - 1 year ago

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Nov 5, 2024, 9:00 AM EST - 1 year ago

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Nov 1, 2024, 12:40 PM EDT - 1 year ago

Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

__AvengerTrader Dec. 4 at 11:37 PM

0 · Reply

CO145 Dec. 4 at 11:23 PM

$CADL @GordonGecko_was_THE_MAN Sounds like FDA considering making one P3 standard vs the current norm of two P3 trials. This should ease your mind regarding the singular Cadl prostate P3.

1 · Reply

Groov Dec. 4 at 11:14 PM

$CADL $18 per Billion.

0 · Reply

Floyd_Dalton Dec. 4 at 11:07 PM

$CADL 10 Billion is well over $100 sp

0 · Reply

svertical1 Dec. 4 at 10:54 PM

$IBRX $CADL $NTLA $CRSP should have doubled today, if not more!

1 · Reply

deporte1800 Dec. 4 at 9:39 PM

$CADL very interesting https://www.statnews.com/pharmalot/2025/12/04/fda-vaccines-pazdur-makary-kennedy-cassidy-vaccines-novo-alzheimers/

0 · Reply

deporte1800 Dec. 4 at 9:37 PM

1 · Reply

Drcando Dec. 4 at 9:04 PM

$CADL Strong Volume today

0 · Reply

ShadowBull3745 Dec. 4 at 9:04 PM

$CADL

0 · Reply

minnesotafarmcountry Dec. 4 at 8:44 PM

$CADL MMs have been collecting shares all day … who sells into a change in sentiment/direction?

1 · Reply

Stocksprofessional Dec. 4 at 8:40 PM

$CADL another 9993 shares added. I couldn’t resist

1 · Reply

Fredminish Dec. 4 at 8:37 PM

$CADL Is this just a runup into R&D day and will it sell off after? Not going to make a major announcement on a Friday at the event.... but at this point that should be the default... there's no rumour to buy (right now)

2 · Reply

tannerwallen03 Dec. 4 at 8:32 PM

$CADL some big buys coming through

0 · Reply

CAN_2409 Dec. 4 at 8:22 PM

$CADL ONE HUNDRED BILLION DOLLARS!

1 · Reply

WallStreetBuyDip Dec. 4 at 8:19 PM

$CADL Massive volume spike with 1,073,616 shares traded, which is higher than the average volume of 1,674,435. Price has been quite volatile, ranging from a low of $4.39 to a high of $12.21 recently. With such high volatility, it might be wise to wait for a lower H% before considering an entry.

0 · Reply

Muffinsss Dec. 4 at 7:34 PM

$CADL that was almost exciting back to collecting

0 · Reply

1Loonie2Toonie Dec. 4 at 7:24 PM

$CADL should reach at least $9 by '26 end.

2 · Reply

Spiderjenkins Dec. 4 at 7:12 PM

$PLRZ thanks for last nights AH boost. Pushed my profits into $CADL heavily now

0 · Reply

Spiderjenkins Dec. 4 at 7:10 PM

$BBAI thanks $SMX for that 40% risky full port last minute. Long on $BBAI $CADL $EPOW & $IBRX

0 · Reply

claybridge Dec. 4 at 6:47 PM

$CADL I've noticed some new folks showing up with questions and opinions. I highly recommend reading Dr Tak's X article from March 1st. Here's a snippet, which shows the pathway the Board likely chose to take. They are advancing NSCLC ph3 next year and possibly Pancreatic. BLA will be rolling, with full submission in Q4 (verified by PPT on X). Approval will be 2-4 months after full submission because of their fast track status and initiating a rolling BLA months in advance of full submission. The Board wants $15-20B. I think they'll get it sometime between 18-24mos from now.

1 · Reply

Spiderjenkins Dec. 4 at 6:35 PM

$CADL $SMX

0 · Reply

ShadowBull3745 Dec. 4 at 6:25 PM

$CADL

0 · Reply

Market Cap	242.65M
Revenue (ttm)	0.00
Net Income (ttm)	-55.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.06

Volume	1,381,400
Avg Vol	766,046
Day's Range	N/A - N/A
Shares Out	54.90M
Stochastic %K	96%
Beta	-0.92
Analysts	Strong Sell
Price Target	$19.29